Document is current

Article History

Received: 6 March 2024

Accepted: 25 July 2024

First Online: 19 August 2024

Declarations

:

: Prior to participant recruitment, the study design was reviewed and approved by a central institutional review board or ethics committee for all countries included in the study.

: Not applicable.

: ML-M, reports personal fees for advisory boards, speaker panels, or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, IPSEN, Lundbeck, Lilly, Medtronic, Menarini, MSD, Novartis, Orion, Pfizer, Reckitt Benckiser, Saint-Jude, Sanofi-Aventis, Teva, UCB, UPSA, and Zambon. EL has received speaker fees and consulting fees from Allergan, Eli Lilly, and Teva Neuroscience; consulting fees from Aralez Pharmaceuticals, McKesson Canada, and Medscape; speaking fees, consulting, and reimbursement for travel from Novartis; and reimbursement for travel from I-GPAC. ZK has been a speaker and/or consultant and/or has received research support from Allergan, Amgen/Novartis, Eli Lilly, Merck, and Teva. RBL reports support for the present study from AbbVie, research support paid to his institution from the Czap Foundation, the National Headache Foundation, the National Institutes of Health, the S&L Marx Foundation, and the US Food and Drug Administration, and personal fees from AbbVie/Allergan, American Academy of Neurology, American Headache Society, Amgen, Biohaven, BioVision, Boston, Dr. Reddy’s (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Teva, Vector, and Vedanta Research. He holds stock/options in Axon, Biohaven, and Manistee. He is the overall principal investigator for the CaMEO-I Study. FS is a consultant, speaker, or scientific advisor for Amgen, Eli Lilly, Otsuka, and Teva, and the national principal investigator in Japan for the CaMEO-I Study. MM serves on the advisory board for Abbott, AbbVie, Eli Lilly, Lundbeck, Pfizer, Salvia, and Teva; has received payment for the development of educational presentations from AbbVie, Eli Lilly, Lundbeck, Pfizer, and Teva; and is the national principal investigator in the United Kingdom for the CaMEO-I Study. KF is managing director of MIST Research which has received research funding from AbbVie, Allay Lamp, Juva Health, NYC Langone Health and GlaxoSmithKline via grants to the National Headache Foundation. AMA and MS are employees of AbbVie and may hold AbbVie stock. KS was an employee of AbbVie at the time this study was conducted and may hold AbbVie stock. DCB has received grant support and honoraria from AbbVie, Amgen, Biohaven, Collegium, Eli Lilly and Company, Lundbeck, and Teva and for work on the editorial board of <i>Current Pain and Headache Reports</i> and is the national principal investigator in the United States for the CaMEO-I Study.